NASDAQ:MBX MBX Biosciences Q4 2025 Earnings Report $60.94 -1.97 (-3.13%) Closing price 09/21/2026 04:00 PM EasternExtended Trading$61.25 +0.31 (+0.51%) As of 07:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast MBX Biosciences EPS ResultsActual EPS-$0.49Consensus EPS -$0.64Beat/MissBeat by +$0.15One Year Ago EPSN/AMBX Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMBX Biosciences Announcement DetailsQuarterQ4 2025Date3/12/2026TimeBefore Market OpensConference Call DateThursday, March 12, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) MBX Biosciences Earnings HeadlinesMBX Biosciences, Inc. (NASDAQ:MBX) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 17, 2026 | americanbankingnews.comMBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.September 22 at 1:00 AM | Paradigm Press (Ad)MBX Biosciences to Participate in Upcoming Investor ConferencesSeptember 9, 2026 | globenewswire.comMBX Biosciences Announces Appointment of Jeff Held as Chief Legal OfficerSeptember 8, 2026 | globenewswire.comMBX Biosciences Begins Pivotal Phase 3 Canvuparatide TrialAugust 27, 2026 | tipranks.comSee More MBX Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MBX Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MBX Biosciences and other key companies, straight to your email. Email Address About MBX BiosciencesMBX Biosciences (NASDAQ:MBX) is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. The company uses its Precision Empowered Peptide platform to design peptide medicines intended to provide targeted biological activity, extended duration and improved dosing convenience. MBX’s lead product candidate is MBX 2109, an investigational long-acting parathyroid hormone replacement therapy being developed for people with hypoparathyroidism. The company is also advancing additional peptide-based candidates intended to address significant unmet needs in endocrine and metabolic disease. Founded in 2018 and headquartered in Indianapolis, Indiana, MBX Biosciences conducts research and clinical development primarily in the United States. Its programs remain investigational and have not been approved for commercial use by the U.S. Food and Drug Administration or other regulatory authorities.View MBX Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep WinningJ.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to Growth Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
